-
1Academic Journal
Συγγραφείς: V. O. Bitsadze, J. Kh. Khizroeva, E. Grandone, R. I. Gabidullina, M. V. Tretyakova, N. A. Makatsariya, N. R. Gashimova, K. N. Grigoreva, A. V. Vorobev, A. V. Lazarchuk, M. M. Muravyova, A. G. Krendeleva, T. E. Polyakova, M. S. Zainulina, D. L. Kapanadze, F. E. Yagubova, J.-C. Gris, I. Elalamy, G. Gerotziafas, P. Van Dreden, A. D. Makatsariya, В. О. Бицадзе, Д. Х. Хизроева, Э. Грандоне, Р. И. Габидуллина, М. В. Третьякова, Н. А. Макацария, Н. Р. Гашимова, К. Н. Григорьева, А. В. Воробьев, А. В. Лазарчук, М. М. Муравьёва, А. Г. Кренделева, Т. Е. Полякова, М. С. Зайнулина, Д. Л. Капанадзе, Ф. Э. Ягубова, Ж.-К. Гри, И. Элалами, Г. Геротзиафас, П. Ван Дреден, А. Д. Макацария
Συνεισφορές: The authors declare no funding, Авторы заявляют об отсутствии финансовой поддержки
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 19, No 3 (2025); 377-388 ; Акушерство, Гинекология и Репродукция; Vol 19, No 3 (2025); 377-388 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: риск тромбообразования, IVF, assisted reproductive technologies, ART, ovarian stimulation, thrombosis, ovarian hyperstimulation syndrome, OHSS, thrombophilia, venous thromboembolism, arterial thrombosis, risk factors, thrombosis prevention, thrombogenesis risk, ЭКО, вспомогательные репродуктивные технологии, ВРТ, стимуляция яичников, тромбоз, синдром гиперстимуляции яичников, СГЯ, тромбофилия, венозная тромбоэмболия, артериальный тромбоз, факторы риска, профилактика тромбозов
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2494/1346; Calhaz-Jorge C., De Geyter C.H., Kupka M.S. et al. Survey on ART and IUI: legislation, regulation, funding and registries in European countries: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod Open. 2020;2020(1):hoz044. https://doi.org/10.1093/hropen/hoz044.; European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE); Smeenk J., Wyns C., De Geyter C. et al. ART in Europe, 2019: results generated from European registries by ESHRE. Hum Reprod. 2023;3(12):2321–38. https://doi.org/10.1093/humrep/dead197.; Farquhar C., Marjoribanks J., Brown J. et al. Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. Reprod Biomed Online. 2017;35(1):3–16. https://doi.org/10.1016/j.rbmo.2017.03.024.; Nelson S.M. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thromb Res. 2013;131 Suppl 1:S1–3. https://doi.org/10.1016/S0049-3848(13)00023-6.; Grandone E., Villani M. Assisted reproductive technologies and thrombosis. Thromb Res. 2015;135 Suppl 1:S44–5. https://doi.org/10.1016/S0049-3848(15)50441-6.; Kupka M.S., Ferraretti A.P., de Mouzon J. et al.; European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE†. Hum Reprod. 2014;29(10):2099–113. https://doi.org/10.1093/humrep/deu175.; Sennström M., Rova K., Hellgren M. et al. Thromboembolism and in vitro fertilization – a systematic review. Acta Obstet Gynecol Scand. 2017;96(9):1045–52. https://doi.org/10.1111/aogs.13147.; Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5 Supple):S188–93. https://doi.org/10.1016/j.fertnstert.2008.08.034.; Grandone E., Colaizzo D., Vergura P. et al. Age and homocysteine plasma levels are risk factors for thrombotic complications after ovarian stimulation. Hum Reprod. 2004;19(8):1796–9. https://doi.org/10.1093/humrep/deh346.; Henriksson P., Westerlund E., Wallén H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:е8632. https://doi.org/10.1136/bmj.e8632.; Rova K., Passmark H., Lindqvist P.G. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100. https://doi.org/10.1016/j.fertnstert.2011.10.038.; Nelson S.M. Prophylaxis of VTE in women – during assisted reproductive techniques. Thromb Res. 2009;123 Suppl 3:S8–S15. https://doi.org/10.1016/S0049-3848(09)70127-6.; Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. No evidence that assisted reproduction increases the risk of thrombosis: a Danish national cohort study. Hum Reprod. 2012;27(5):1499–503. https://doi.org/10.1093/humrep/des041.; Serour G.I., Aboulghar M., Mansour R. et al. Complications of medically assisted conception in 3,500 cycles. Fertil Steril. 1998;70(4):638–42. https://doi.org/10.1016/s0015-0282(98)00250-7.; Girolami A., Scandellari R., Tezza F. et al. Arterial thrombosis in young women after ovarian stimulation: case report and review of the literature. J Thromb Thrombolysis. 2007;24(2):169–74. https://doi.org/10.1007/s11239-007-0009-9.; Chan W.S. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21(3):207–18. https://doi.org/10.1097/GCO.0b013e328329c2b8.; Yang S., Yuan J., Qin W. et al. The clinical characteristics of acute cerebrovascular accidents resulting from ovarian hyperstimulation syndrome. Eur Neurol. 2017;77(5–6):221–30. https://doi.org/10.1159/000463383.; Filipovic-Pierucci A., Gabet A., Deneux-Tharaux C. et al. Arterial and venous complications after fertility treatment: a French nationwide cohort study. Eur J Obstet Gynecol Reprod Biol. 2019;237:57–63. https://doi.org/10.1016/j.ejogrb.2019.02.034.; Chan W.S, Dixon M.E. The "ART" of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008;121(6):713–26. https://doi.org/10.1016/j.thromres.2007.05.023.; Villani M., Favuzzi G., Totaro P. et al. Venous thromboembolism in assisted reproductive technologies: comparison between unsuccessful versus successful cycles in an Italian cohort. J Thromb Thrombolysis. 2018;45(2):234–9. https://doi.org/10.1007/s11239-017-1584-z.; Mozes M., Bogokowsky H., Antebi E. et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet. 1965;2(7424):1213–5. https://doi.org/10.1016/s0140-6736(65)90636-7.; Kermode A.G., Churchyard A., Carroll W.M. Stroke complicating severe ovarian hyperstimulation syndrome. Aust N Z J Med. 1993;23(2):219–20. https://doi.org/10.1111/j.1445-5994.1993.tb01823.x.; Inbar O.J., Levran D., Mashiach S., Dor J. Ischemic stroke due to induction of ovulation with clomiphene citrate and menotropins without evidence of ovarian hyperstimulation syndrome. Fertil Steril. 1994;62(5):1075–6. https://doi.org/10.1016/s0015-0282(16)57078-2.; Cluroe A.D., Synek B.J. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995;27(4):344–6. https://doi.org/10.1080/00313029500169273.; Chan W.S., Ginsberg J.S. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the 'ART' behind the clot. J Thromb Haemost. 2006;4(8):673–7. https://doi.org/10.1111/j.1538-7836.2006.02026.x.; Fleming T., Sacks G., Nasser J. Internal jugular vein thrombosis following ovarian hyperstimulation syndrome. Aust N Z J Obstet Gynaecol. 2012;52(1):87–90. https://doi.org/10.1111/j.1479-828X.2011.01392.x.; Salomon O., Schiby G., Heiman Z. et al. Combined jugular and subclavian vein thrombosis following assisted reproductive technology – new observation. Fertil Steril. 2009;92(2):620–5. https://doi.org/10.1016/j.fertnstert.2008.07.1708.; Aboulghar M.A., Mansour R.T., Serour G.I., Amin Y.M. Moderate ovarian hyperstimulation syndrome complicated by deep cerebrovascular thrombosis. Hum Reprod. 1998;13(8):2088–91. https://doi.org/10.1093/humrep/13.8.2088.; Kodama H., Fukuda J., Karube H. et al. Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. Fertil Steril. 1995;64(6):1207–9. https://doi.org/10.1016/s0015-0282(16)57987-4.; Delvigne A., Demoulin A., Smitz J. et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod. 1993;8(9):1353–60. https://doi.org/10.1093/oxfordjournals.humrep.a138260.; Dulitzky M., Cohen S.B., Inbal A. et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril. 2002;77(3):463–7. https://doi.org/10.1016/s0015-0282(01)03218-6.; Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: Data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.; Olausson N., Discacciati A., Nyman A.I. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: nationwide cohort study. J Thromb Haemost. 2020;18(8):1965–73. https://doi.org/10.1111/jth.14840.; Abramov Y., Elchalal U., Schenker J.G. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. 1998;70(6):1070–6. https://doi.org/10.1016/s0015-0282(98)00350-1.; Bauersachs R.M., Manolopoulos K., Hoppe I. et al. More on: the 'ART' behind the clot: solving the mystery. J Thromb Haemost. 2007;5(2):438–9.; Richardson M.A., Berg D.T., Calnek D.S. et al. 17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway. Endocrinology. 2000;141(10):3908–11. https://doi.org/10.1210/endo.141.10.7798.; Rogolino A., Coccia M.E., Fedi S. et al. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis. 2003;14(3):277–82. https://doi.org/10.1097/01.mbc.0000061296.28953.d0.; Ricci G., Bogatti P., Fischer-Tamaro L. et al. Factor V Leiden and prothrombin gene G20210A mutation and in vitro fertilization: prospective cohort study. Hum Reprod. 2011;26(11):3068–77. https://doi.org/10.1093/humrep/der261.; Goualou M., Noumegni S., de Moreuil C. et al. Venous thromboembolism associated with assisted reproductive technology: a systematic review and meta-analysis. Thromb Haemost. 2023;123(3):283–94. https://doi.org/10.1055/s-0042-1760255.; Pabinger I., Grafenhofer H., Kaider A. et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005;3(5):949–54. https://doi.org/10.1111/j.1538-7836.2005.01307.x.; Milenkovic J., Milojkovic M., Mitic D. et al. Interaction of thrombophilic SNPs in patients with unexplained infertility-multifactor dimensionality reduction (MDR) model analysis. J Assist Reprod Genet. 2020;37(6):1449–58. https://doi.org/10.1007/s10815-020-01808-4.; Santos T.D.S., Ieque A.L., de Carvalho H.C. et al. Antiphospholipid syndrome and recurrent miscarriage: A systematic review and meta-analysis. J Reprod Immunol. 2017;123:78–87. https://doi.org/10.1016/j.jri.2017.09.007.; El Hasbani G., Khamashta M., Uthman I. Antiphospholipid syndrome and infertility. Lupus. 2020;29(2):105–17. https://doi.org/10.1177/0961203319893763.; Qublan H.S., Eid S.S., Ababneh H.A. et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod. 2006;21(10):2694–8. https://doi.org/10.1093/humrep/del203.; Nesbit C., Gunalp C., Zhang J. et al. Longitudinal assessment of coagulation potential before, during, and following an in vitro fertilization cycle. Thromb Res. 2024;238:97–102. https://doi.org/10.1016/j.thromres.2024.04.020.; Azem F., Many A., Ben Ami I. et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod. 2004;19(2):368–70. https://doi.org/10.1093/humrep/deh069.; Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–7. https://doi.org/10.1093/humrep/det458.; Refsum H., Nurk E., Smith A.D. et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136(6 Suppl):1731S–1740S. https://doi.org/10.1093/jn/136.6.1731S.; Fuchs H.E., O'Connell K., Du M. et al. Vitamin B12 supplementation and vitamin B12 blood serum levels: evaluation of effect modification by gender and smoking status. Nutr Cancer. 2022;74(7):2373–83. https://doi.org/10.1080/01635581.2021.2007271.; Bazzano L.A., He J., Muntner P. et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003;138(11):891–7. https://doi.org/10.7326/0003-4819-138-11-200306030-00010.; Villani M., Dentali F., Colaizzo D. et al. Pregnancy-related venous thrombosis: comparison between spontaneous and ART conception in an Italian cohort. BMJ Open. 2015;5(10):e008213. https://doi.org/10.1136/bmjopen-2015-008213.; Rosendaal F.R. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82(2):610–9.; Grandone E., Ageno W. The legacy of Edwards and Steptoe and the windy roads of assisted reproduction: where do we stand with venous thromboembolism? Thromb Haemost. 2023;123(3):267–9. https://doi.org/10.1055/a-1996-1341.; Yinon Y., Pauzner R., Dulitzky M. et al. Safety of IVF under anticoagulant therapy in patients at risk for thrombo-embolic events. Reprod Biomed Online. 2006;12(3):354–8. https://doi.org/10.1016/s1472-6483(10)61009-7.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300.; Grandone E., Piazza G. Thrombophilia, inflammation, and recurrent pregnancy loss: a case-based review. Semin Reprod Med. 2021;39(1–02):62–8. https://doi.org/10.1055/s-0041-1731827.; Sticchi E., Romagnuolo I., Cellai A.P. et al. Fibrinolysis alterations in infertile women during controlled ovarian stimulation: influence of BMI and genetic components. Thromb Res. 2012;130(6):919–24. https://doi.org/10.1016/j.thromres.2012.07.005.; Gurunath S., Vinekar S., Biliangady R. Assisted reproductive techniques in a patient with history of venous thromboembolism: a case report and review of literature. J Hum Reprod Sci. 2018;11(2):193–7. https://doi.org/10.4103/jhrs.JHRS5817.; Westerlund E., Antovic A., Hovatta O. et al. Changes in von Willebrand factor and ADAMTS13 during IVF. Blood Coagul Fibrinolysis. 2011;22(2):127–31. https://doi.org/10.1097/MBC.0b013e32834363ea.; https://www.gynecology.su/jour/article/view/2494
-
2Academic Journal
Συγγραφείς: S. A. Shaposhnikov, S. V. Sinkov, I. B. Zabolotskikh
Πηγή: Вестник хирургии имени И.И. Грекова, Vol 172, Iss 6, Pp 059-063 (2018)
Θεματικοί όροι: профилактика тромбозов, абдоминальная хирургия, thromboprophylaxis, abdominal surgery, Surgery, RD1-811
Περιγραφή αρχείου: electronic resource
Σύνδεσμος πρόσβασης: https://doaj.org/article/52f23f124fca47e582c3d505716c9641
-
3Academic Journal
Συγγραφείς: A. V. Vorobyov, A. D. Makatsariya
Πηγή: Медицинский совет, Vol 0, Iss 2, Pp 79-85 (2016)
Θεματικοί όροι: низкомолекулярный гепарин, thrombosis prophylaxis, low molecular weight heparin, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, гепарин-индуцированная тромбоцитопения профилактика тромбозов, fact, Medicine, oral anticoagulants, heparin-induced thrombocytopenia, пероральные антикоагулянты, ингибиторы xa-фактора
Σύνδεσμος πρόσβασης: https://www.med-sovet.pro/jour/article/download/45/45
https://doaj.org/article/b961a93b89ed4f25a128fd7b8560eca3
https://www.med-sovet.pro/jour/article/view/45
https://cyberleninka.ru/article/n/patogeneticheskie-osobennosti-profilaktiki-trombogemorragicheskih-oslozhneniy-u-onkoginekologicheskih-bolnyh
https://www.med-sovet.pro/jour/article/viewFile/45/45 -
4Academic Journal
Συγγραφείς: A. V. Vorobiev, A. D. Makatsaria, А. В. Воробьев, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 11, No 3 (2017); 88-93 ; Акушерство, Гинекология и Репродукция; Vol 11, No 3 (2017); 88-93 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: нарушения гемостаза, genetic thrombophilia, acquired thrombophilia, anticoagulant therapy, malignant neoplasms, thrombotic complications, pathogenesis of thrombotic complications, cancer patient, prevention of thrombosis, hemostasis disorders, генетическая и приобретенная тромбофилия, антикоагулянтная терапия, злокачественные новообразования, тромботические осложнения, патогенез тромботических осложнений, онкологические больные, профилактика тромбозов
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/430/629; Keeling D., Klok F.A., Le Gal G. Controversies in venous thromboembolism. 2015. Blood Rev. 2016; 30 (1): 27-33.; Thalin C., Blomgren B., Mobarrez F., Lundstrom A., Laska A.C., von Arbin M. et al. Trousseau's Syndrome, a Previously Unrecognized Condition in Acute Ischemic Stroke Associated With Myocardial Injury. J Investig Med High Impact Case Rep. 2014; 2 (2): 1-6.; Semb V.B., Tveit A. Limited malignancy screening of patients with idiopathic venous thromboembolism. Tidsskr Nor Laegeforen. 2014; 134 (4): 407-1.; Sebastiani G.D., Iuliano A., Cantarini L., Galeazzi M. Genetic aspects of the antiphospholipid syndrome: An update. Autoimmun Rev. 2016; 15 (5): 433-9.; Chen F., Wang M.J., Li J., Yan C.E., Han X.H., Wu Z.Y., Qi J. Plasma D-dimer value as a predictor of malignant lymph node involvement in operable non-small cell lung cancer. Tumour Biol. 2015; 36 (12): 9201-7.; Zhang M.H., Xu X.H., Wang Y., Linq Q.X., Bi Y.T., Miao X.J. et al. A prognostic biomarker for gastric cancer with lymph node metastases. Anat Rec (Hoboken).; Tozzoli R., D'Aurizio F., Falcomer F., Basso S.M., Lumachi F. Serum Tumor Markers in Stage I-II Breast Cancer. Med Chem. 2016; 12 (3): 285-9.; Martínez-Lostao L., Anel A., Pardo J. How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clin Cancer Res. 2015; 21 (22): 5047-56.; Duffy M.J., McGowan P.M., Harbeck N., Thomssen C., Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014; 16 (4): 428.; Ansari D., Ansari D., Andersson R., Andrén-Sandberg A. Pancreatic cancer and thromboembolic disease, 150 years after Trousseau. Hepatobiliary Surg Nutr. 2015; 4 (5): 325-35.; Couturaud F., Meyer G., Mottier D. Thrombophilia and the Risk of Recurrent Venous Thromboembolism – Reply. JAMA. 2015; 314 (18): 1976.; Pabinger I., Ay C., Dunkler D., Thaler J., Reitter E.M., Marosi C. et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS). J Thromb Haemost. 2015; 13 (1): 17-22.; Kovac M., Kovac Z., Tomasevic Z., Vucicevic S., Djordjevic V., Pruner I., Radojkovic D. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen – results from a prospective, single center, case control study. Eur J Intern Med. 2015; 26 (1): 63-7.; Segers O., Simioni P., Tormene D., Bulato C., Gavasso S., Rosing J., Castoldi E. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. J Thromb Haemost. 2012; 10 (1): 73-80.; Cooper P.C., Rezende S.M. An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations. Int J Lab Hematol. 2007; 29 (3): 153-62.; White C.W., Thomason A.R., Prince V. Recurrent venous thromboembolism in a patient with heterozygous factor V Leiden mutation. Hosp Pharm. 2014; 49 (8): 748-51.; Zhang P., Zhang J., Sun G., Gao X., Wang H., Yan W. et al. Risk of Budd-Chiari syndrome associated with factor V Leiden and G20210A prothrombin mutation: a meta-analysis. PLoS One. 2014; 9 (4): e95719.; Van Cott E.M., Khor B., Zehnder J.L. Factor V Leiden. Am J Hematol. 2016; 91 (1): 46-9.; Naushad S.M., Reddy C.A., Kumaraswami K., Divyya S., Kotamraju S., Gottumukkala S.R., Digumarti R.R., Kutala V.K. Impact of hyperhomocysteinemia on breast cancer initiation and progression: epigenetic perspective. Cell Biochem Biophys. 2014; 68 (2): 397-406.; Heit J.A. Predicting the risk of venous thromboembolism recurrence. Am J Hematol. 2012; 87 (Suppl 1): S63-7.; Falanga A., Russo L., Milesi V. The coagulopathy of cancer. Curr Opin Hematol. 2014; 21 (5): 423-9.; Levi M. Cancer-related coagulopathies. Thromb Res. 2014; 133 (Suppl 2): S70-5.; Li N. Platelets in cancer metastasis: To help the «villain» to do evil. IntJCancer. 2016; 138 (9): 2078-87.; https://www.gynecology.su/jour/article/view/430
-
5Academic Journal
Συγγραφείς: M. A. Satybaldyeva, T. M. Reshetnyak, М. А. Сатыбалдыева, Т. М. Решетняк
Πηγή: Rheumatology Science and Practice; Vol 54, No 2 (2016); 219-226 ; Научно-практическая ревматология; Vol 54, No 2 (2016); 219-226 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20162
Θεματικοί όροι: пероральные антикоагулянты, prevention of thromboses, oral anticoagulants, профилактика тромбозов
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2221/1437; Насонов ЕЛ, редактор. Антифосфолипидный синдром. Москва: Литтерра; 2004. 424 с. [Nasonov EL, editor. Antifosfolipidnyi sindrom [Antifosfolipid syndrome]. Moscow: Litterra; 2004. 424 p.].; Решетняк ТМ. Антифосфолипидный синдром: диагноз и принципы терапии. Сonsilium medicum. 2002;(4):408-15 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and treatment principles. Сonsilium Medicum. 2002;(4):408-15 (In Russ.)].; Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56–71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (A Lecture). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.)]. doi:10.14412/1995-4484-2014-56-71; Erkan D, Pierangeli SS, editors. Antiphospholipid syndrome: insights and highlights from the 13th International Congress on Antiphospholipid Antibodies. New York: Springer Science+Business Media; 2012. doi:10.1007/978-1-4614-3194-7_17; Asherson RA, Cervera R, Piette J-Ch, Shoenfeld Y, editors. The antiphospholipid syndrome II: Autoimmune thrombosis. New York: Elsevier; 2002. P. 3-445.; Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x; Levine J, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-63. doi:10.1056/NEJMra002974; Алекберова ЗС, Решетняк ТМ, Раденска СГ и др. Васкулопа- тия у больных системной красной волчанкой с антифосфоли- пидным синдромом. Терапевтический архив. 1995;(5):41-4 [Alekberova ZS, Reshetnyak TM, Radenska SG, et al. Vasculopathy in patients with systemic lupus erythematosus with antiphospholipid syndrome. Terapevticheskii Arkhiv. 1995;(5):41-4 (In Russ.)].; Lie JT. Pathology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The antiphospholipid syndrome. Boca Raton, Fl.: CRC Press; 1996. P. 89-104.; Austin S, Cohen H. Antiphospholipid syndrome. Medicine. 2009;34:472-5. doi:10.1053/j.mpmed.2006.08.012; Середавкина НВ, Решетняк ТМ. IX Европейский форум по антифосфолипидным антителам. Краткий обзор. Научно-пра- ктическая ревматология. 2014;52(1):115-21 [Seredavkina NV, Reshetnyak TM. The IX European forum on antiphospholipid antibodies. A brief review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):115-21 (In Russ.)]. doi:10.14412/1995-4484-2014-115-121; Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-94S. doi:10.1378/chest.11-2301 PMID: 22315268; Keeling D, Baglin T, Tait C, et al. British Committee for Standards in Haematology (BCSH) – Guidelines for General Haematology, Haemostasis and Thrombosis. Guidelines on oral anticoagulation with warfarin fourth edition. Br J Haematol. 2011;154:311-24. doi:10.1111/j.1365-2141.2011.08753.x. Epub 2011 Jun 14. PMID: 21671894; Ruiz-Irastorza G, Crowther M, Branch W, Khamashta M. Antiphospholipid syndrome. Lancet. 2010;376:1498-509. doi:10.1016/S0140-6736(10)60709-X. Epub 2010 Sep 6. PMID: 20822807; Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep. 2013 Jun;15(6):331. doi:10.1007/s11926-013-0331-5. PMID: 23649961; Boehringer Ingelheim International GmBH, 21/09/2012. Available from: www.emc.medicines.org.uk; Xarelto 10 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of first authorisation/ renewal of authorisation: 30/09/08. Date of revision 12/2011. Available from: www.emc.medicines.org.uk; Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57. doi:10.1146/annurev-med- 062209-095159. PMID: 21226611; Frost C, Yu Z, Nepal S, et al. Apixaban, an oral direct, factor Xa inhibitor: multiple ascending-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007;5 Suppl 2:P-M-664.; Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-9. doi:10.1016/j.ahj.2009.07.035. PMID: 20211292; Patel M; for the ROCKET AF Study Investigators. Rivaroxaban – Once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-7. doi:10.1016/j.ahj.2009.11.025; Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011 Oct;72(4):581-92. doi:10.1111/j.1365- 2125.2011.03916.x. PMID:21241354; Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, orapixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systemic review and metaanalysis of subgroups. Thrombosis. 2013;2013:640723. doi:10.1155/2013/640723. Epub 2013 Dec 22. PMID: 24455237; Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1056/NEJMoa0905561. Epub 2009 Aug 30. PMID: 19717844; Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor Ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003 Nov 22;362(9397):1691-8. PMID:14643116; Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005 Feb 9;293(6):690-8. PMID: 15701910; Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med. 2013 Jul;80(7):443-51. doi:10.3949/ccjm.80a.13025. PMID: 23821689; Erikkson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatranetexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the Re-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-85. doi:10.1111/j.1538-7836.2007.02748.x; Schulman S, Kakkar AK, Goldhaber SZ, et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. doi:10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16. PMID: 24344086; NICE technology appraisal guidance 249. Dabigatranetexilate for the prevention of stroke and systemic embolism in atrial fibrillation.March 2012. Available from: www.nice.org.uk/TA249; Approval Drugs by FDA. Available from. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs; Guidance in development. Pulmonary embolism (acute treatment, VTE prevention) – rivaroxaban [ID569]. Available from: www.nice.org.uk; Danowski A, de Azevedo MN, de Souza Papi JA, et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009 Jun;36(6):1195-9. doi:10.3899/jrheum.081194. Epub 2009 May 15. PMID: 19447935; Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.Rheumatology (Oxford). 2002 Aug;41(8):924-9. PMID: 12154210; Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009 Mar;68(3):397-9. doi:10.1136/ard.2008.096669. Epub 2008 Sep 23. PMID: 18812393; Gage BF. Can we rely on Re-LY? N Engl J Med. 2009 Sep 17;361(12):1200-2. doi:10.1056/NEJMe0906886. Epub 2009 Aug 30. PMID: 19717843; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010 Nov 4;363(19):1875- 6. doi:10.1056/NEJMc1007378. PMID: 21047252; Turpie AG, Lassen MR, Davidson BL, et al; RECORD 4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4): a randomised trial. Lancet. 2009;373:1673-80. doi:10.1016/S0140- 6736(09)60734-0. Epub 2009 May 4. PMID: 19411100; Patel MR, Mahaffey KW, Gar J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (and supplementary appendix). N Engl J Med. 2011;365:883-91. doi:10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957; NICE technology appraisal guidance 256. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. May 2012. Available from: www.nice.org.uk/TA256; EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix). N Engl J Med. 2010;363:2499-510. doi:10.1056/NEJMoa1007903. Epub 2010 Dec 3. PMID: 21128814; Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039. Epub 2011 Aug 27. PMID: 21870978; Eliquis 2.5 mg film-coated tablets film-coated tablets Summary of Product Characteristics (SPC) last updated on the eMC: 03/12/2012. Available from: www.emc.medicines.org.uk; Guidance in development. Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) – apixaban [ID500]. Available from: www.nice.org.uk; Reference ID: 3212129. Available from: www.accessdata.fda.gov/ scripts/cder/drugsatfda; NICE technology appraisal guidance 261. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. July 2012. Available from: www.nice.org.uk/TA 261; Guidance in development. Dabigatranetexilate for the treatment of acute venous thromboembolic events (ID108). Available from: www.nice.org.uk; Xarelto 20 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer Health Care AG. Last updated on the eMC: 04/ 12/2012. Available from: www.emc.medicines.org.uk; EINSTEIN-PE Investigators, Bü ller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi:10.1056/NEJMoa1113572. Epub 2012 Mar 26. PMID: 22449293; Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;36(6):594-604. doi:10.1056/NEJMoa0810773. PMID: 19657123; Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-15. doi:10.1016/S0140-6736(09)62125-5. PMID: 20206776; Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement (ADVANCE-3). N Engl J Med. 2010;363(26):2487-98. doi:10.1056/NEJMoa1006885. PMID: 21175312; NICE technology appraisal guidance 245.Venous thromboembolism – apixaban (hip and knee surgery). January 2012. Available from: www.nice.org.uk/TA 245; Schulman S, Kearon C, Kakkar, et al; for the Re-COVER Study Group. Dabigatran versus warfarin for the treatment of acute venous thromboembolism. N Engl Med. 2009;361:2341-52. doi:10.1056/NEJMoa0906598. PMID: 19966341; Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708. doi:10.1056/NEJMoa1207541. Epub 2012 Dec 8. PMID: 23216615; Development status of rivaroxaban, apixabanedoxaban and dabigatran. Available from: www.clinicaltrials.gov; Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Ann Rev Pharmacol Toxicol. 2012;52:79-99. doi:10.1146/annurev-pharmtox-010611-134633. Epub 2011 Aug 5. PMID: 21819239; Pengo V, Crippa L, Falanga A, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost. 2012;10(10):1979- 87. doi:10.1111/j.1538-7836.2012.04866.x. PMID: 22827490; Buller HR. Once-daily oral rivaroxaban versus placebo in the longterm prevention of recurrent symptomatic venous thromboembolism, the Einstein-Extension Study. Late Breaking Abstracts LBA-2. 51st ASH Annual Meeting and Exposition; 2009.; Harder S. Renal profiles of anticoagulants. J Clin Pharmacol. 2012;52(7):964-75. doi:10.1177/0091270011409231. Epub 2011 May 24. PMID: 21610202; Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19:486-91. doi:10.1177/0961203310361355. PMID: 20353992; Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidence from British Committee for Standards in Haematology. Br J Haematol. 2012;159(4):427-9. doi:10.1111/bjh.12052. PMID: 22970737; Ryn J, Stangier J, Haertter S, et al. Dabigatranetexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 Jun;103(6):1116-27. doi:10.1160/TH09-11-0758. Epub 2010 Mar 29. PMID: 20352166; Pradaxa®. Summary of Product Characteristics, 2011. Boehringer Ingelheim.; Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. doi:10.1111/j.1365- 2125.2006.02667.x. PMID: 17061960; Van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012 Apr;125(4):417-20. doi:10.1016/j.amjmed.2011.10.017. Epub 2012 Feb 3. PMID: 22306274; Agarwal MB, Verma S, Mahapatra M, et al. Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian J Hematol Blood Transfus. 2012 Sep;28(3):129-43. doi:10.1007/s12288-012-0167- 6. Epub 2012 Jul 28. PMID: 23997448; Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013 Nov;69(11):1875-81. doi:10.1007/s00228-013-1550-4. Epub 2013 Jun 20. PMID: 23784008; Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012 Mar;23(2):138-43. doi: 0.1097/MBC.0b013e32834f1b0c. PMID: 22227958; Martinuzzo ME, Barrera LH, D’Adamo MA, et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. 2014;36(2):144-50. doi:10.1111/ijlh.12138. Epub 2013 Sep 6. PMID: 24034808; Makris M, Joost J, van Veen JJ, et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haem. 2012;160:35-46. doi:10.1111/bjh.12107. Epub 2012 Nov 1. PMID: 23116425; Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876-86. doi:10.1160/TH12- 03-0209. Epub 2012 Sep 26. PMID: 23014816; Spyropoulos ACD, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954-62. doi:10.1182/blood-2012-06-415943. Epub 2012 Aug 28. PMID: 22932800; Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-23. doi:10.1182/blood-2011-10- 378950. Epub 2012 Feb 1. PMID: 22302737; Llau JV, Ferrandis R. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol. 2009;22:661-6. doi:10.1097/ACO.0b013e32832eb8ab. PMID: 19568169
-
6Academic Journal
Συγγραφείς: A. V. Vorobev, A. D. Makatsaria, А. В. Воробьев, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 8, No 2 (2014); 139-148 ; Акушерство, Гинекология и Репродукция; Vol 8, No 2 (2014); 139-148 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: НЕФРАКЦИОНИРОВАННЫЙ ГЕПАРИН, cancer patients, thrombosis prevention, hemostasis abnormalities, low molecular weight heparin, unfractionated heparin, ОНКОЛОГИЧЕСКИЕ БОЛЬНЫЕ, ПРОФИЛАКТИКА ТРОМБОЗОВ, НАРУШЕНИЯ ГЕМОСТАЗА, НИЗКОМОЛЕКУЛЯРНЫЙ ГЕПАРИН
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/79/80; Воробьев А.В. Злокачественные заболевания и тромбозы. Вопросы акушерства, гинекологии и перинатологии. 2008; 2 (7): 18-25.; Макацария А.Д., Воробьев А.В., Чабров А.М. Значение оценки маркеров тромбофилии при проведении химио- и лучевой терапии у онкологических больных. Материалы Российского Медицинского Форума-2006 «Фундаментальная наука и практика», 18-20 октября 2006 г.; Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. Монография. М. 2008; 650 с.; Цыб А.Ф., Сушкевич Г.Н., Балуда М.В., Воробьев А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онкологических больных (солидные образования). Пособие для врачей. Обнинск. 2008; 42 с.; Agnelli G., Bergqvist D., Cohen A. et al. Randomized doubleblind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study [abstract]. Blood. 2003; 102: 15a.; Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A., Cetin M., Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2004; 2: 1266-71.; Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E.The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126 (3): 204-233. Erratum in: Chest. 2005 Jan; 127 (1): 415-6.; Bergqvist D., Agnelli G., Cohen A.T. et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N. Engl. J. Med. 2002; 346: 975-980.; Bona R.D. Hickcy A.D. Wallace D.M. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am. J. Clin. Oncol. 2000: 23: 71-73.; Borsig L., Wong R., Feramisco J. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. 2001; 98: 3352-3357.; Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126 (3): 401-428.; Dolovich L., Ginsberg J.S., Douketis J.D. et al. A meta-analysis comparing low molecular weight heparins to unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med. 2000; 160: 181-188.; Eikelboom J.W., Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J. Thromb. Haemost. 2007; 5 (1): 255-63.; Falanga A. Mechanism of hypercoagulation in malignancy and during chemotherapy. Haemostasis. 1998; 28 (3): 50-60.; Gouin-Thibault I., Achkar A., Samama M.M. The thrombophilic state in cancer patients. Acta Haematol. 2001; 106 (1-2): 33-42.; Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., Rustin G., Thomas M., Quigley M., Williamson R.C. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 2004; 22: 1944-8.; Kearon C., Ginsberg J.S., Kovacs M. et al. Comparison of low-intensity warfarin therapy with conventional intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N. Engl. J. Med. 2003; 349:631-639.; Kleber F.X., Flosbach C.W., Koppenhagen K. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III/IV (PRINCE II study). Circulation. 1999; 100 (1): 1-619.; Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., Prandoni P., Bos M.M., Richel D.J., van T.G., Buller H.R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005; 23: 2130-5.; Lee A.Y., Levine M.N., Baker R.I. et al. Lowmolecular-weight heparin versus a oumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2003; 349: 146-153.; Levine M.N., Lee A.Y. Treatment of venous thrombosis in the cancer patient. Acta Haematol. 2001; 106 (1-2): 81-87.; Ludwig R.J., Alban S., Bistrian R., Boehncke W.H., Kaufmann R., Henschler R., Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb. Haemost. 2006; 95: 535-40.; Monreal M., Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol. 2001; 106 (1-2): 69-72.; Nasir F.A., Patel H.K., Scully M.F., Fareed J., Lemoine N.R., Kakkar A.K. The low molecular weight heparins dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumour model (abstract 2993). Blood. 2003; 102.; Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch. Intern. Med. 2000; 160: 3415-20.; Shaker A. Mousa. Low-Molecular-Weight Heparin in Thrombosis and Cancer. Seminars in thrombosis and hemostasis. 2004; 30: 25-29.; Vorobiev A.V., Makatsaria A.D., Chabrov A.M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiology of haemostasis and thrombosis. 2006; 35 (1-2): A20.; von Tempelhoff G.F., Harenberg J., Niemann F. et al. Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int. J. Oncol. 2000; 16: 815-82.; https://www.gynecology.su/jour/article/view/79
Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/79
-
7Academic Journal
Συγγραφείς: A. V. Vorobev, A. M. Chabrov, A. A. MD, Ph.D., head of gynecological department, S. V. Bulgakova, A. D. Makatsariya, А. В. Воробьев, А. М. Чабров, А. А. Савченко, С. В. Булгакова, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 9, No 2 (2015); 99-109 ; Акушерство, Гинекология и Репродукция; Vol 9, No 2 (2015); 99-109 ; 2500-3194 ; 2313-7347 ; 10.17749/2313-7347.2015.9.2
Θεματικοί όροι: нарушения гемостаза, malignancies, thrombotic complications, hemostasis system, metastasis of tumor tissue, DIC, thrombophilia, pathogenesis of thrombotic complications, cancer patients, prevention of thrombosis, hemostasis disorders, злокачественные новообразования, тромботические осложнения, система гемостаза, метастази- рование опухолевой ткани, ДВС-синдром, тромбофилия, патогенез тромботических осложнений, онкологические больные, профилактика тромбозов
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/162/163; Воробьев А.В. Состояние тромбоцитарного звена гемостаза у онкогинекологических больных. Материалы VI российского форума «Мать и дитя». 2004: 318-319.; Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбо- филия, тромбозы. Монография. М. 2008; 650 с.; Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложне- ний. Ассоциация флебологов России, Всероссийское общество хирургов. М. 2010.; Цыб А.Ф., Сушкевич Г.Н., Балуда М.В., Воро- бьев А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онколо- гических больных (солидные образования). Пособие для врачей. Обнинск. 2008; 42 с.; Bharthuar A., Khorana A.A., Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013; 132: 180-184.; Chaturvedi S., Sidana S., Elson R., Khorana A.A., McCrae K.R. Symptomatic and incidental venousthromboembolic disease are both associated withmortality in patients with prostate cancer. PLoSOne 2014; 9: e94048.; Claussen C., Rausch A.V., Spath B. et al. Clinical significance of hemostatic activation markers inwomen with suspected ovarian cancer. Oncol Res Treat. 2014; 37: 669.; Dammacco F., Vacca A., Procaccio P. et al. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a singlecenter of internal medicine. ClinExp Med 2013; 13: 85-97.; Davila M., Robles-Carrillo L., Unruh D. et al. Microparticle association and heterogeneity oftumor-derived tissue factor in plasma: is it important for coagulation activation? ThrombHaemost. 2014; 12: 186-196.; Demers M., Wagner D.D. NETosis: a new factor intumor progression and cancer-associated thrombosis. SeminThrombHemost. 2014; 40: 277-283.; Fuchs T.A., Brill A., Wagner D.D. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. ArteriosclerThromb Vase Biol. 2012; 32: 1777-1783.; Geddings J.E., Mackman N. Tumor-derived tissuefactor-positive microparticles and venous thrombosisincancer patients. Blood. 2013; 122: 1873-1880.; Hernandez C., Orbe J., Roncal C. et al. Tissue factorexpressed by microparticles is associated withmortality but not with thrombosis in cancer patients. ThrombHaemost. 2013; 110: 598-608.; Hyman D.M., Soff G.A., Kampel L.J. Disseminatedintravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review ofthe literature. Oncology. 2011; 81: 119-125.; Khorana AA. Risk assessment for cancerassociated thrombosis: what is the best approach? Thromb Res. 2012; 129: 10-15.; Kitchens C.S. The contact system. Arch Pathol Lab Med. 2002 Nov; 126 (11): 1382-6.; Kocatiirk B., Versteeg H.H. Tissue factor isoformsin cancer and coagulation: may the best isoformwin. Thromb Res 2012; 129: 69-75.; Langer F., Bokemeyer C. Crosstalk between cancerand haemostasis. Implications for cancer biologyand cancer-associated thrombosis with focus ontissue factor. Hamostaseologie. 2012; 32: 95-104.; Lo L., Valentine H., Harrison J. et al. Tissue factorexpression in the metaplasia-adenomacarcinomasequence of gastric cancer in a European population. Br I Cancer. 2012; 107: 1125-1130; Mackman N. New insights into the mechanisms ofvenous thrombosis. J Clin Invest. 2012; 122: 2331-2336.; Rak J., Yu J.L., Luyendyk J., Mackman N. Oncogenes, trousseau syndrome, and cancerrelated changesin the coagulome of mice and humans. Cancer Res. 2006: 66: 10643-10646.; Sack G.H. Jr, Levin J., Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeuticfeatures. Medicine (Baltimore) 1977; 56: 1-37.; Thaler J., Preusser M., Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res. 2013; 131: 162-165.; Thaler I., Ay C., Mackman N. et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathologicalfeatures. Eur I Clin Invest. 2013; 43: 277-285.; Trousseau A. Phlegmasiaalbadolens. Clinique Medicale de l'Hotel-Dieu de Paris. 1865; 3: 654-712.; Varki A. Trousseaus syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110; 1723-1729.; Vorobiev A.V., Makatsaria A.D., Chabrov A.M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiology of haemostasis and thrombosis. 2006; 35 (1-2): A20.; Van Doormaal F.K. Terpstra W., Van Der Griend Ret al. Is extensive screening for cancer in idiopathicvenous thromboembolism warranted? J ThrombHaemost. 2011; 9: 79-84.; https://www.gynecology.su/jour/article/view/162
-
8Academic Journal
Συγγραφείς: Kh. L. Atabaeva, Х. Л. Атабаева
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 8, No 1 (2014); 34-36 ; Акушерство, Гинекология и Репродукция; Vol 8, No 1 (2014); 34-36 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: ОСЛОЖНЕННАЯ БЕРЕМЕННОСТЬ, pathogenesis of thrombotic complications, thrombosis prevention, preeclampsia, complicated pregnancy, ПАТОГЕНЕЗ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ, ПРОФИЛАКТИКА ТРОМБОЗОВ, ГЕСТОЗ
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/60/61; Абаева И.Ш. Клиническое значение контроля за маркерами воспаления у беременных с синдромом потери плода и тромбофилией. Автореферат дис. канд. мед. наук. М. 2011; 23 с.; Бицадзе В.О. Патогенез, принципы диагностики и профилактики осложнений беременности, обусловленных тромбофилией. Дисс. …докт. мед. наук. М., 2004.; Бицадзе В.О, Макацария А.Д., Хизроева Д.Х. и др. Тромбофилия как важнейшее звено патогенеза осложнений беременности. Практическая медицина. 2012; 5: 22-29.; Гадаева З.К. Частота и спектр полиморфизмов провоспалительных цитокинов и тромбофилии у беременных с метаболическим синдромом и гестозом. Материалы X юбилейного Всероссийского научного форума Мать и Дитя. М. 2009; 42 с.; Дубоссарская З.М., Дука Ю.М. Место тромбофилии в структуре синдрома потери плода. Таврический медико-биологический вестник. 2011; 14 (3; 1); 75-77.; Макацария А.Д., Бицадзе В.О. Тромбофилии и противотромботическая терапия в акушерской практике. М. 2003; 904 с.; Bick R.L. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin. Appl. Thromb. Hemost. 2000 Jul; 6 (3): 115-25.; Brenner B. Thrombophilia and pregnancy. Clin. Adv. Hematol. Oncol. 2003 Jun; 1 (6): 351-5.; Goodlin R. С Preeclampsia as the great impostor. Amer. J. Obstet. Gynec. 1991; 164: 1577-81.; Karpman D., Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie. 2013 May 29; 33 (2): 96-104.; Mazhar S.B., Emanuel A. Haematological defects in recurrent pregnancy loss. Haematology Updates. 2011: 56-60.; McCrae K.R., Cines D.B.Thrombotic microangiopathy during pregnancy. Seminhematol. 1997; 34 (2): 148-58.; https://www.gynecology.su/jour/article/view/60
Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/60
-
9Academic Journal
Συγγραφείς: A. V. Vorobev, A. M. Chabrov, A. A. Savchenko, A. D. Makatsariya, А. В. Воробьёв, А. М. Чабров, А. А. Савченко, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 10, No 1 (2016); 26-37 ; Акушерство, Гинекология и Репродукция; Vol 10, No 1 (2016); 26-37 ; 2500-3194 ; 2313-7347 ; 10.17749/2313-7347.2016.10.1
Θεματικοί όροι: ингибиторы Xa-фактора, oral anticoagulants, heparin-indused thrombocytopenia, thrombosis prophylaxis, anti- Xa drugs, пероральные антикоагулянты, гепарин-индуцированная тромбоцитопения, профилактика тромбозов
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/33/523; Воробьёв А.В. Злокачественные заболевания и тромбозы. Вопросы акушерства, гинекологии и перинатологии. 2008; 2 (7): 18-25.; Макацария А.Д., Воробьёв А.В., Чабров А.М. Значение оценки маркеров тромбофилии при проведении химио- и лучевой терапии у онкологических больных. Материалы Российского Медицинского форума – 2006 «Фундаментальная наука и практика», 18-20 октября 2006 г.; Макацария А.Д., Воробьёв А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. М. 2008; 650 с.; Макацария А.Д. и соавт. Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей под редакцией А.Д. Макацария. М. 2011.; Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Ассоциация флебологов России, Всероссийское общество хирургов. М. 2010.; Цыб А.Ф., Сушкевич Г.Н., Балуда М.В., Воробьёв А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онкологических больных (солидные образования). Пособие для врачей. Обнинск. 2008; 42 стр.; Шилова А.Н., Лазарев А.Ф., Воробьёв П.А., Баркаган З.С., Ходоренко С.А., Котовщикова Е.Ф., Момот А.П., Буевич Е.И. Контролируемая антитромботическая профилактика онкотромбозов: клинико-экономический анализ. Сибирский онкологический журнал. 2008; 3: 74-76; Agnes Y.Y. Lee, M.D., Mark N. Levine, M.D., Ross I. Baker, M.D., Chris Bowden, M.D., Ajay K. Kakkar, M.B., Martin Prins, M.D., Frederick R. Rickles, M.D., Jim A. Julian, M.Math., Susan Haley, B.Sc., Michael J. Kovacs, M.D., Michael Gent. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2003; 349: 146-153.; Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003; 22: 6524-36.; David Bergqvist, Giancarlo Agnelli, Alexander T. Cohen, Amiram Eldor, Paul E. Nilsson, Anne Le Moigne-Amrani, Flavia Dietrich-Neto F. ENOXACAN II Investigators. Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer. N; Engl J Med. 2002; 346: 975-980.; Drugs. Establishing Active Ingredient Sameness for Generic Enoxaparin Sodium, a Low Molecular Weight Heparin. 2010 July 28.; Donati M.B., A. Falanga: Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol. 2001; 106: 18-24.; EMEA. Guidelines on Clinical and Non-Clinical Development of Medicinal Products Containing Low-Molecular-Weight Heparins. London: European Medical Agency; 2009. EMEA/CHMP/BMWP/11826407enfin.pdf. 2010 July 29.; Falanga A., Marchetti M., Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer. 2004; 30: 11-23.; FDA News Release. fda.gov/NewsEvents/Newsroorn/PressAnnouncements/ucm220092.hm. Дата обращения: 23.07.2015.; Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low-molecularweight heparin. Thromb Haemost. 2008; 99: 807-18.; Gray E., Rigsby P., Behr-Gross M.E. Collaborative study to establish the lowmolecular- mass heparin for assay – European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio. 2004; 1: 59-76.; Guerrini M., Guglieri S., Naggi A., Sasisekharan R., Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost. 2007; 33: 478-87.; Harenberg J., Kakkar A., Bergqvist D. et al. On behalf of the Subcommittee on Control of Anticoagulalion of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemoslasis. Recommendations on biosimiliar lowmolecular- weight heparins. J ThrombHaemost. 2009; 7 (7): 1222-1225.; Hirsh J., Warkentin T.E., Shaughnessy S.G. et al: Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119: Suppl. 1: 64-94.; Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J. Clin. Oncol. 2004; 22 (10): 1944-1948.; Kalodiki E., Leon W. SASAT and Task Force on Generic LMWHs. SASAT (South Asian Society on Atherosclerosis and Thrombosis) proposal for regulatory guidelines for generic low molecular weight heparins (LMWHs). Clin Appl Thromb Hemost. 2009; 15 (1): 8-11.; Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005; 23 (10): 2130-2135.; Lee AYY. Screening for occult cancer in patients with idiopathic venous thromboembolism. J Thromb Haemost. 2003; 1: 2273-2274.; Meyer G., Marjanovic Z., Valcke J. et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer a randomized controlled study. Arch. Intern. Med. 2002; 162 (15): 1729-1735.; New Oral Anticoagulants and the Cancer Patient theoncologist.com/article/new-oralanticoagulants-and-cancer-patient.; New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? Kenneth A. Bauer MD. Journal of Thrombosis and Thrombolysis. February 2006; 21 (1): 67-72.; North American Thrombosis Forum Official Policy Statement regarding the protection of patient safety and patient rights on the matter of follow-on biologies. natfonIine.org/ NATFbiologiessta-tement.php. Дата обращения: 26.07.2010.; Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484- 3488.; Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism.; Lancet Oncol. 2005 Jun; 6 (6): 401-10.; Prandoni P., Lensing A.W., Buller H.R. et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 1992; 327 (16): 1128-1133.; Samama M.M., Gerotziafas G. Comparative Pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000; 26: 31-6.; Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000; 160: 3415-20.; van Dongen C.J., Mac Gillavry M.R., Prins M.H. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. 2005; 3. Art. № CD003074.; WHO 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). who.int/biologicaIs/areas/biologicaI_thcrapeutic/BIOTHERAPETUTICS_FOR_WEB_22APRIL2010_WI. Дата обращения: 18.08.2015.; Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis. 2003; 29: 239-46.; https://www.gynecology.su/jour/article/view/33
-
10Academic Journal
Συγγραφείς: A. D. Makatsariya, A. V. Vorobev, A. M. Chabrov, A. A. Savchenko, A. L. Mishchenko, А. Д. Макацария, А. В. Воробьёв, А. М. Чабров, А. А. Савченко, А. Л. Мищенко
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 10, No 1 (2016); 84-98 ; Акушерство, Гинекология и Репродукция; Vol 10, No 1 (2016); 84-98 ; 2500-3194 ; 2313-7347 ; 10.17749/2313-7347.2016.10.1
Θεματικοί όροι: VEGF, thrombotic complications, hemostatic system, metastasis of tumor tissue, the immune system, DIC, thrombophilia, inflammation, hemodynamic disorders, angiogenesis, pathogenesis of thrombotic complications, cancer patients, prevention of thrombosis, hemostasis disorders, TF, тромботические осложнения, система гемостаза, метастазирование опухолевой ткани, иммунная система, ДВС-синдром, тромбофилия, воспаление, гемодинамические нарушения, неоангиогенез, патогенез тромботических осложнений, онкологические больные, профилактика тромбозов, нарушения гемостаза
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/38/527; Блинов Д.В., Терентьев С.С. Характеристика биохимических маркеров нарушения проницаемости гематоэнцефалического барьера и функционирования центральной нервной системы. Нейрохимия. 2013; 30 (3): 179-192.; Блинов Д.В. Современные представления о роли нарушения резистентности гематоэнцефалического барьера в патогенезе заболеваний ЦНС. Часть I: строение и формирование гематоэнцефалического барьера. Эпилепсия и пароксизмальные состояния. 2013; 3: 65-75.; Блинов Д.В. Современные представления о роли нарушения резистентности гематоэнцефалического барьера в патогенезе заболеваний ЦНС. Часть II: строение и формирование гематоэнцефалического барьера. Эпилепсия и пароксизмальные состояния. 2014; 1: 70-84.; Блинов Д.В. Пациенты с неврологическими расстрой ствами: обоснование необходимости фармакоэкономической оценки оптимизации затрат на ведение с использованием ней роспецифических белков в качестве маркеров повышения проницаемости гематоэнцефалического барьера. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2014; 7 (1): 40-45.; Воробьев А.В. Злокачественные заболевания и тромбозы. Вопросы гинекологии, акушерства и перинатологии. 2008; 2 (7): 18-25.; Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. Монография. М. 2008; 650 с.; Цыб А.Ф., Сушкевич Г.Н., Балуда М.В., Воробьев А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онкологических больных (солидные образования). Пособие для врачей. Обнинск. 2008; 42 с.; Abildgaard U., Lindahl A.K., Sandset P.M. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis. 1991; 21: 254-7.; Ay C., Vormittag R., Dunkler D. et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009; 27 (25): 4124-4129.; Batsis J.A., Morgenthaler T.I. Trousseau syndrome and the unknown cancer: use of positron emission tomographic imaging in a patient with a paraneoplastic syndrome. Mayo Clin Proc. 2005 Apr; 80 (4): 537-4.; Bell W.R., Starksen N.F., Tong S., Porterfield J.K. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med. 1985; 79: 423-30.; Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003; 22: 6524-36.; Donati M.B., Falanga A. Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol. 2001; 106: 18-24.; Falanga A., Marchetti M., Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer. 2004; 30: 11-23.; Gouin-Thibault I., Achkar A., Samama M.M. The thrombophilic state in cancer patients. Acta Haematol. 2001; 106 (1-2): 33-42.; Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low-molecularweight heparin. Thromb Haemost. 2008; 99: 807-18.; Khorana A.A., Ahrendt S.A., Ryan C.K. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007; 13 (10): 2870-2875.; Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5 (3): 632-634.; Khorana A.A., Francis C.W., Menzies K.E. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008; 6 (11): 1983-1985.; Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010; 125 (6): 490-493.; Lee A.Y.Y. Screening for occult cancer in patients with idiopathic venous thromboembolism. J Thromb Haemost. 2003; 1: 2273-2274.; Ludwig R.J., Alban S., Bistrian R., Boehncke W.H., Kaufmann R., Henschler R., Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006; 95: 535-40.; Mandala M., Clerici M., Corradino I. et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’ Ann Oncol. 2012; 23 (6): 1416-1421.; Menapace L.A., Peterson D.R., Berry A., Sousou T. and Khorana A.A. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 106 (2): 371-378.; Monreal M., Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol. 2001; 106 (1-2): 69-72.; Moore R.A., Adel N., Riedel E. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011; 29 (25): 3466-3473.; Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484-3488.; Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005 Jun; 6 (6): 401-10.; Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000; 160: 3415-20.; Shaker A. Mousa. Low-Molecular-Weight Heparin in Thrombosis and Cancer. Seminars in thrombosis and hemostasis. 2004; 30: 25-29.; Sørensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343 (25): 1846-1850.; von Tempelhoff G.F., Harenberg J., Niemann F. et al. Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 2000; 16: 815-824.; Wun T.C. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood. 1992; 79: 430-8.; Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis 2003; 29: 239-46.; https://www.gynecology.su/jour/article/view/38
-
11Academic Journal
Συγγραφείς: M. S. Selkhadzhieva, М. С. Селхаджиева
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 8, No 1 (2014); 31-33 ; Акушерство, Гинекология и Репродукция; Vol 8, No 1 (2014); 31-33 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: ОСЛОЖНЕННАЯ БЕРЕМЕННОСТЬ, fetal loss syndrome, antiphospholipid syndrome, thrombosis prevention, preeclampsia, complicated pregnancy, СИНДРОМ ПОТЕРИ ПЛОДА, АНТИФОСФОЛИПИДНЫЙ СИНДРОМ, ПРОФИЛАКТИКА ТРОМБОЗОВ, ГЕСТОЗ
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/59/60; Бицадзе В.О. Патогенез, принципы диагностики и профилактики осложнений беременности, обусловленных тромбофилией. Дисс. …докт. мед. наук. М. 2004; 271 с.; Громыко Г.Л. Роль антифосфолипидного синдрома в развитии акушерских осложнений. Проблемы репродукции. 1997; 4: 13-18.; Макацария А.Д. Антифосфолипидный синдром М. 2000; 373 с.; Макацария А.Д., Бицадзе В.О. Тромбофилии и противотромботическая терапия в акушерской практике. М. 2003; 904 с.; Матвеева Т.Е. Вопросы патогенеза и профилактики синдрома потери плода у беременных с тромбофилией. Дисс. .канд. мед. наук. М. 2002; 131 с.; Сухих Г.Л., Пономарева И.В., Городничева Ж.А., Ванько Л.В. Спектр антифосфолипидных антител у беременных с гестозом. Акушерство и гинекология. 1998; 5: 22-26.; Amergual O., Atsumi T., Khamashta M.A, Tinohones F., Hughes G.R.V. Autoantibodies against oxidazed low density lipoprotein in antiphospholipid syndrome. Br. J. Rheumatol. 1997; 36: 964-968.; Backos M., Rai R., Baxter N., Chilcott I.T, Cohen H., Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low-dose aspirin and heparin. Br. Obstet Gynaecol. 1999; 106: 102-7.; Bates S.M., Greer I.A., Pabinger I., Sofaer S., Hirsh J. Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Evidence-Based Clinical Practice Guidelines American College of Chest Physicians (8th Edition). Chest. 2008; 133; 844-886.; Botet F., Romera G., Montagut P., Figueras J., Carmona J., Balasch J. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J. Perinat. Med. 1997; 25: 192-196.; Cowchock S. Antibodies and pregnancy loss. The New Eng. Journal of Medicine. July 17, 1997; 197-198.; de Laat B., Mertens K., de Groot Ph. Mechanisms of disease: antiphospholipid antibodies -from clinical association to pathologic mechanism nature clinical practice / B. de Laat, K. Mertens, Ph. de Groot. Rheumatology. 2008; 4 (4): 192-199.; Empson M., Lassere M., Craig J.C., Scott J.R. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet. Gynecol. 2002; 99:135-44.; Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet. Gynecol. 2002; l00: 408-13.; Gandra M.J., Fraga M., Saraiva J.P., Andrade J. Anticardiolipin antibodies and high risk pregnancy. 16th Congress on thromb and haemost. Porto. 2000; abstr. p. 160.; Genievskaya M., Makatsaria A. Low molecular weight heparin (Fraxiparine) as long-term single agent therapy in pregnant with antiphospholipid syndrome. 16th Congress oh thrombosis and haemostasis. Porto. 2000, abstr. p. 161.; Granger K.A., Farquharson R.G., Obstetric outcome in antiphosholipid syndrome. Lupus. 1997; 6: 509-513.; Honig A. Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages / A. Honig et al. Hum. Reprod. 2010; 25 (11): 2753-2754.; Levy R.A., Avvad E., Olivera J., Porto L.C. Placental pathology in antiphospholipid syndrome. Lupus. 1998; 7 (2): 81-85.; Lyden T.W., Vogt E., Ng A.K., Johnson P.M., Rote N.S. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. Reprod Immunol. 1992; 22: 1-14.; Zeev Blumenfeld, Benjamin Brenner. Thrombophilia-associated pregnancy wastage. Fertility and sterility. Nov. 1999; 72 (5): 765-774.; https://www.gynecology.su/jour/article/view/59
Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/59
-
12Academic Journal
Συγγραφείς: САТЫБАЛДЫЕВА МАРИЯ АЗАМАТОВНА, РЕШЕТНЯК Т.М.
Περιγραφή αρχείου: text/html
-
13Academic Journal
Συγγραφείς: МАКАЦАРИЯ АЛЕКСАНДР ДАВИДОВИЧ, ВОРОБЬЁВ АЛЕКСАНДР ВИКТОРОВИЧ, ЧАБРОВ АНДРЕЙ МИХАЙЛОВИЧ, САВЧЕНКО АЛЕКСАНДР АНАТОЛЬЕВИЧ, МИЩЕНКО АЛЕКСАНДР ЛЕОНИДОВИЧ
Περιγραφή αρχείου: text/html
-
14Academic Journal
Συγγραφείς: ВОРОБЬЁВ АЛЕКСАНДР ВИКТОРОВИЧ, ЧАБРОВ АНДРЕЙ МИХАЙЛОВИЧ, САВЧЕНКО АЛЕКСАНДР АНАТОЛЬЕВИЧ, МАКАЦАРИЯ АЛЕКСАНДР ДАВИДОВИЧ
Περιγραφή αρχείου: text/html
-
15Academic Journal
Συγγραφείς: ВОРОБЬЕВ АЛЕКСАНДР ВИКТОРОВИЧ, МАКАЦАРИЯ АЛЕКСАНДР ДАВИДОВИЧ, ЧАБРОВ АНДРЕЙ МИХАЙЛОВИЧ, САВЧЕНКО АЛЕКСАНДР АНАТОЛЬЕВИЧ
Περιγραφή αρχείου: text/html
-
16Academic Journal
Συγγραφείς: ВОРОБЬЕВ А.В., ЧАБРОВ А.М., САВЧЕНКО А.А., БУЛГАКОВА С.В., МАКАЦАРИЯ А.Д.
Περιγραφή αρχείου: text/html
-
17Academic Journal
Συγγραφείς: Воробьев, А., Макацария, А.
Θεματικοί όροι: ПАТОГЕНЕЗ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ, ОНКОЛОГИЧЕСКИЕ БОЛЬНЫЕ, ПРОФИЛАКТИКА ТРОМБОЗОВ, НАРУШЕНИЯ ГЕМОСТАЗА, НИЗКОМОЛЕКУЛЯРНЫЙ ГЕПАРИН, НЕФРАКЦИОНИРОВАННЫЙ ГЕПАРИН
Περιγραφή αρχείου: text/html
-
18Academic Journal
Συγγραφείς: Бокарев, И., Попова, Л.
Θεματικοί όροι: АРТЕРИАЛЬНЫЕ ТРОМБОЗЫ, ВЕНОЗНЫЕ ТРОМБОЗЫ, ПРОФИЛАКТИКА ТРОМБОЗОВ
Περιγραφή αρχείου: text/html
-
19Academic Journal
Συγγραφείς: Селхаджиева, М.
Θεματικοί όροι: ТРОМБОФИЛИЯ, СИНДРОМ ПОТЕРИ ПЛОДА, АНТИФОСФОЛИПИДНЫЙ СИНДРОМ, ПРОФИЛАКТИКА ТРОМБОЗОВ, ГЕСТОЗ, ОСЛОЖНЕННАЯ БЕРЕМЕННОСТЬ
Περιγραφή αρχείου: text/html
-
20Academic Journal
Συγγραφείς: Атабаева, Х.
Θεματικοί όροι: ТРОМБОФИЛИЯ, ПАТОГЕНЕЗ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ, ПРОФИЛАКТИКА ТРОМБОЗОВ, ГЕСТОЗ, ОСЛОЖНЕННАЯ БЕРЕМЕННОСТЬ
Περιγραφή αρχείου: text/html
